Literature DB >> 20528340

Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis.

Albert Roger1, Josep Fortea, Sheila Mora, Maite Artés.   

Abstract

AIM: To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis. PATIENTS AND METHODS: This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18 years) with allergic rhinitis who presented with a prescription for ebastine FDT. Via a telephone interview, patients were asked to evaluate the characteristics of ebastine FDT in comparison with their previous experience with other antihistamines.
RESULTS: 100 patients with allergic rhinitis were included in the study (41 had intermittent disease, 57 persistent disease and two with unknown disease states). Patients rated ebastine FDT very highly (mean scores: 4.5-4.7 out of a possible 5) for all characteristics related to convenience, such as easy to take, easy to carry around in a bag or pocket, suitable for taking anytime/anywhere, and convenient to use. A total of 85% of patients perceived ebastine FDTs onset of action to be fast or very fast, and 77% indicated that it acted faster than their usual antihistamine. A total of 96% were satisfied or very satisfied with ebastine FDT and 98% were interested in using the drug again.
CONCLUSIONS: Patients with rhinitis rate ebastine FDT very highly in terms of its formulation, convenience of use and its rapid onset of action. These characteristics resulted in a high level of individual satisfaction with the new formulation and a clear preference by the majority of patients to use ebastine FDT in the future.

Entities:  

Year:  2008        PMID: 20528340     DOI: 10.1586/14737167.8.4.337

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  3 in total

1.  Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters.

Authors:  Bhawana Dhakal; Jaybir Kumar Thakur; Reema Kumari Mahato; Ishwori Rawat; D C Rabin; Rahul Rana Chhetri; Kedar Prasad Shah; Atul Adhikari; Jitendra Pandey
Journal:  ScientificWorldJournal       Date:  2022-05-19

2.  Clinical utility and patient adherence with ebastine for allergic rhinitis.

Authors:  Giorgio Ciprandi
Journal:  Patient Prefer Adherence       Date:  2010-10-14       Impact factor: 2.711

3.  Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.

Authors:  S Rico; Rm Antonijoan; Mj Barbanoj
Journal:  J Asthma Allergy       Date:  2009-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.